WO2004062563A3 - Methods for screening for therapeutic agents that are useful in the treatment of oxytocin and vasopressin-related disorders - Google Patents

Methods for screening for therapeutic agents that are useful in the treatment of oxytocin and vasopressin-related disorders Download PDF

Info

Publication number
WO2004062563A3
WO2004062563A3 PCT/IB2004/000109 IB2004000109W WO2004062563A3 WO 2004062563 A3 WO2004062563 A3 WO 2004062563A3 IB 2004000109 W IB2004000109 W IB 2004000109W WO 2004062563 A3 WO2004062563 A3 WO 2004062563A3
Authority
WO
WIPO (PCT)
Prior art keywords
oxytocin
vasopressin
screening
treatment
useful
Prior art date
Application number
PCT/IB2004/000109
Other languages
French (fr)
Other versions
WO2004062563A2 (en
Inventor
Daniel Huber
Ron Stoop
Original Assignee
Univ Lausanne
Daniel Huber
Ron Stoop
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Lausanne, Daniel Huber, Ron Stoop filed Critical Univ Lausanne
Publication of WO2004062563A2 publication Critical patent/WO2004062563A2/en
Publication of WO2004062563A3 publication Critical patent/WO2004062563A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5058—Neurological cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9406—Neurotransmitters
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9406—Neurotransmitters
    • G01N33/9426—GABA, i.e. gamma-amino-butyrate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Abstract

The invention provides a method of screening, in an in vitro system, of an agent useful in the treatment of oxytocin or vasopressin related disorders or conditions wherein said agent is able to modulate the inhibition by oxytocin of a vasopressin-activated neuron in the central amygdala after oxytocin sensitive neurons activation from the central amygdala, said method comprising the steps of: a) co-contacting an oxytocin agonist-or antagonist- and said agent with oxytocin sensitive neurons from the central amygdala, b) detecting whether said agent activates or inhibits vasopressin sensitive neurons of the central amygdala.
PCT/IB2004/000109 2003-01-16 2004-01-16 Methods for screening for therapeutic agents that are useful in the treatment of oxytocin and vasopressin-related disorders WO2004062563A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44043103P 2003-01-16 2003-01-16
US60/440,431 2003-01-16

Publications (2)

Publication Number Publication Date
WO2004062563A2 WO2004062563A2 (en) 2004-07-29
WO2004062563A3 true WO2004062563A3 (en) 2004-12-29

Family

ID=32713551

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2004/000109 WO2004062563A2 (en) 2003-01-16 2004-01-16 Methods for screening for therapeutic agents that are useful in the treatment of oxytocin and vasopressin-related disorders

Country Status (1)

Country Link
WO (1) WO2004062563A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11966429B2 (en) 2021-08-06 2024-04-23 On Time Staffing Inc. Monitoring third-party forum contributions to improve searching through time-to-live data assignments

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007025249A2 (en) 2005-08-26 2007-03-01 The Board Of Trustees Of The Leland Stanford Junior University Methods for treatment of headaches by administration of oxytocin
PT3242676T (en) 2015-01-07 2023-12-06 TONIX Pharmaceuticals Holding Corp Magnesium-containing oxytocin formulations and methods of use
JP6113798B2 (en) * 2015-09-09 2017-04-12 株式会社Ｍｃｂｉ Biomarker for cognitive dysfunction disease and method for detecting cognitive dysfunction disease using the biomarker
US10736880B2 (en) 2015-12-18 2020-08-11 The Board Of Regents Of The University Of Texas Systems Therapeutics for preterm labor management
WO2019165129A1 (en) * 2018-02-22 2019-08-29 The Board Of Trustees Of The Leland Stanford Junior University Methods for diagnosing and for determining severity of an autism spectrum disorder
EP3759121A1 (en) * 2018-03-01 2021-01-06 Trigemina, Inc. Labeled oxytocin and method of manufacture and use
US10963841B2 (en) 2019-03-27 2021-03-30 On Time Staffing Inc. Employment candidate empathy scoring system
US10728443B1 (en) 2019-03-27 2020-07-28 On Time Staffing Inc. Automatic camera angle switching to create combined audiovisual file
US11127232B2 (en) 2019-11-26 2021-09-21 On Time Staffing Inc. Multi-camera, multi-sensor panel data extraction system and method
CN111296331B (en) * 2020-03-09 2022-05-13 广西壮族自治区水产科学研究院 Artificial breeding and seedling raising method for pelteobagrus fulvidraco
US11023735B1 (en) 2020-04-02 2021-06-01 On Time Staffing, Inc. Automatic versioning of video presentations
US11144882B1 (en) 2020-09-18 2021-10-12 On Time Staffing Inc. Systems and methods for evaluating actions over a computer network and establishing live network connections
US11423071B1 (en) 2021-08-31 2022-08-23 On Time Staffing, Inc. Candidate data ranking method using previously selected candidate data
US11907652B2 (en) 2022-06-02 2024-02-20 On Time Staffing, Inc. User interface and systems for document creation

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000025781A1 (en) * 1998-10-29 2000-05-11 Board Of Regents, The University Of Texas System Use of thiazolidinediones derivatives for preventing uterine contractions in premature labour or lactation

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000025781A1 (en) * 1998-10-29 2000-05-11 Board Of Regents, The University Of Texas System Use of thiazolidinediones derivatives for preventing uterine contractions in premature labour or lactation

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BOHUS B, KOOLHAAS J M, KORTE S M, ROOZENDAAL B, WIERSMA A: "Forebrain Pathways and their Behavioural Interactions with Neuroendocrine and Cardiovascular Function in the Rat", CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, vol. 23, no. 2, 1996, pages 177 - 182, XP009034150 *
HUBER D, RAGGENBASS M, STOOP R: "Vasopressin Increases the Frequency of Inhibitory Postsynaptic Currents in the Rat Central Amygdala through Presynaptic Modulation of Neuronal Firing Rate", SOCIETY FOR NEUROSCIENCE ABSTRACTS, vol. 27, no. 1, 2001, pages 382, XP009034396 *
KATO F, FREUND-MERCIER M-J: "Effect of Oxytocin on Rat Central Amygdala Neurons: A Patch Clamp Study in the Slice", JAPANESE JOURNAL OF PHARMACOLOGY, vol. 73, no. Suppl. 1, 1997, pages 249P, XP009034182 *
LU Y-F., HATTORI Y, YAMASHITA H, HORI Y: "Responses to Vasopressin and Oxytocin of Rat Central Amygdala Neurons in vitro", JAPANESE JOURNAL OF PHYSIOLOGY, vol. 45, no. Suppl. 1, 1995, pages S147, XP009034246 *
M. CONDÉS-LARA, P. VEINANTE, M. RABAI, M.J. FREUND-MERCIER: "Correlation between Oxytocin Neuronal Sensitivity and Oxytocin-Binding Sites in the Amygdala of the Rat: Electrophysiological and Histoautoradiographic Study", BRAIN RESEARCH, vol. 637, no. 1-2, 1994, pages 277 - 286, XP002289716 *
VEINANTE P, FREUND-MERCIER M-J: "Distribution of Oxytocin- and Vasopressin-binding Sites in the Rat Extended Amygdala: A Histoautoradiographic Study", JOURNAL OF COMPARATIVE NEUROLOGY, vol. 383, no. 3, 1997, pages 305 - 325, XP009034392 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11966429B2 (en) 2021-08-06 2024-04-23 On Time Staffing Inc. Monitoring third-party forum contributions to improve searching through time-to-live data assignments

Also Published As

Publication number Publication date
WO2004062563A2 (en) 2004-07-29

Similar Documents

Publication Publication Date Title
WO2004062563A3 (en) Methods for screening for therapeutic agents that are useful in the treatment of oxytocin and vasopressin-related disorders
WO2007047852A3 (en) Systems and methods for patient interactive neural stimulation and/or chemical substance delivery
WO2007047854A3 (en) Methods and systems for establishing parameters for neural stimulation
WO2003069332A3 (en) Detection and/or monitoring of synuclein-related diseases
WO2006012639A3 (en) Method of diagnosing, monitoring and treating pulmonary diseases
DE602004010407D1 (en) FLUORO-SUBSTITUTED OMEGA-CARBOXYARYLDIPHENYL-UREA FOR THE TREATMENT AND PREVENTION OF DISEASES AND SUFFERING
WO2003083067A3 (en) Histone deacetylase inhibitors for the treatment of multiple sclerosis, amyotrophic lateral sclerosis and alzheimer's disease
WO2004066820A3 (en) Systems and methods for reducing the likelihood of inducing collateral neural activity during neural stimulation threshold test procedures
WO2003093499A3 (en) Therapeutic use of selective pde10 inhibitors
WO2002082904A3 (en) Method of treating or retarding the development of blindness
EP1755654A4 (en) Methods and systems for treatment of neurological diseases of the central nervous system
WO2004084943A8 (en) Use of antagonists of ghrelin or ghrelin receptor to treat intestinal inflammation
WO2003101282A3 (en) Methods and systems for drug screening and computational modeling
WO2006078853A3 (en) Thioredoxin interacting protein (txnip) as regulator of vascular function
WO2004033666A3 (en) Method and compounds for inhibiting hec1 activity for the treatment of proliferative diseases
WO2002090925A3 (en) Polypeptides and nucleic acids associated with cancer
WO2006086159A3 (en) Method for monitoring early treatment response
WO2004045376A3 (en) Screening methods to identify treatments for autoimmune disease
WO2004030618A3 (en) Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
AU2003233715A1 (en) Use of inhibitors of phospholipase a2 for the treatment, prevention or diagnosis of neural inflammatory or demyelinating disease
WO2004016751A3 (en) Methods of treating neurodegenerative diseases
WO2004038045A3 (en) Method for diagnosing diffuse-type gastric cancer
WO2005101013A3 (en) Materials and methods for screening modulators of neural regneration
BR0314541A (en) Treatment of dementia and parkinson's disease
WO2006078776A3 (en) Inhibitors and methods of treatment of cardiovascular diseases, and methods for identifying inhibitors

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase